One Is More Than Two: Does This Add Up?

    loading  Checking for direct PDF access through Ovid


Synopsis: In this prospective, nonblinded, randomized trial involving 22 centers and 211 patients, meropenem was found to be more efficacious than the combination of ceftazidime and tobramycin for the initial empiric treatment of hospital-acquired bacterial pneumonia. Satisfactory clinical responses occurred in 89% of the meropenem-treated patients and 72% of the ceftazidime-tobramycin-treated patients, with the corresponding bacteriologic response rates being 89% and 67%, respectively; all differences were statistically significant.Source: Sieger B et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study.

    loading  Loading Related Articles